AfterQuery | $30,000,000 | (Apr 10, 2026)
Plume (YC S24) | $3,900,000 | (Apr 10, 2026)
Rork | $15,000,000 | (Apr 10, 2026)
Renasant Bio
United States
- Berkeley, California
- 11/07/2025
- Seed
- $54,500,000
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
- Industry Biotechnology Research
- Website https://www.renasantbio.com/
- LinkedIn https://www.linkedin.com/company/renasant-bio/
Related People
Emily ConleyFounder
United States -
San Francisco Bay Area
Strategic biotech executive with a proven track record of advancing disruptive platforms in drug
development. Architect of visionary partnerships across pharma and biotech (big cap to small cap).
Expert at scaling: joined 23andMe at 30 employees and helped grow it to 600+. Deep scientific
expertise with 35 academic publications. Industry thought-leader with national TV appearances.
Named one of the “20 under 40” leaders in biotech. Multiple board appointments. Big-picture thinker,
who is passionate about healthcare with a gift for inspiring teams and helping companies thrive.
Haast | $12,000,000 | (Apr 10, 2026)
CareGlance Srl | $4,092,182 | (Apr 10, 2026)
Elorian AI | $55,000,000 | (Apr 10, 2026)
TeiaCare & Ancelia: AI for Care Homes | $8,184,645 | (Apr 10, 2026)
Sigma Automate | $2,750,000 | (Apr 10, 2026)
Felix(1) | $1,700,000 | (Apr 10, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
Golden Analytics | $7,000,000 | (Apr 9, 2026)